Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma

145 Background: Neoadjuvant chemotherapy is now the standard of care of patients with resectable gastric carcinomas (GC). Predictive molecular markers and histopathological evidence of tumour response to chemotherapy are not widely available. In this study we evaluated HER2 status and histopathological features associated with tumor regression in 36 GC treated with neoadjuvant chemotherapy followed by surgery. Methods: 36 patients had received ECF, DCF or ECX chemotherapy prior the surgery. The entire tumor beds of the specimens were histologically evaluated. HER2 expression by immunohistochemistry was detected in the biopsy and gastrectomy specimens. Results: 46% of the cases were intestinal type, 40% were diffuse and 14% were unclassified. Nine patients had major clinical and radiological response (CRR) characterized by presence of viable tumor cells less than 50% of the tumor with increased fibrosis (>50%). Three cases had complete CRR showing tumor beds totally replaced by fibrosis. The remaining cases had minimal CRR characterized by viable tumor cells in more than 50% and minimal fibrosis. Necrosis was not found; mucinous metaplasia was observed in three cases of the major CRR. Inflammatory infiltrated was found in all cases. The downstaging of T-stage seems to be greater in the intestinal type than diffuse type (80% vs 44%). HER2+ (score 3) was detected in 16,6% of the biopsy specimen. Only 1 case was HER2+ in the biopsy and in the gastrectomy tissue. All the HER2+ GC showed minimal CRR. Conclusions: The ratio of viable tumor cells and fibrosis is directly associated with tumor response to preoperative chemotherapy. The chemotherapy regimens seem to collaborate to downstaging rates; however the treatment of HER2+ GC group could be improved by the use of Ttrastuzumab.

Download Full-text

18F-FDG PET/CT performed immediately after percutaneous ablation to evaluate outcomes of the procedure: preliminary results

Radiologia Brasileira ◽

10.1590/0100-3984.2018.0010 ◽

2019 ◽

Vol 52 (1) ◽

pp. 24-32 ◽

Cited By ~ 2

Author(s):

Juliana Romanato ◽

Marcos Roberto Menezes ◽

Allan de Oliveira Santos ◽

Regis Otaviano Franca Bezerra ◽

Mariana Cunha Lopes Lima ◽

...

Keyword(s):

Tumor Cells ◽

Predictive Value ◽

Fdg Pet ◽

Percutaneous Ablation ◽

Viable Tumor ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct ◽

Pet Ct Scan ◽

Residual Viable Tumor

Abstract Objective: To determine whether 18F-fluorodeoxyglucose positron emission tomography/computed tomography performed immediately after percutaneous ablation (iPA18F-FDG PET/CT) is useful in evaluating the outcomes of the procedure. Materials and Methods: This was a retrospective study of 20 patients (13 males, 7 females; mean age, 65.8 ± 12.1 years) submitted to percutaneous ablation of metastases. All of the lesions treated had shown focal uptake on a 18F-FDG PET/CT scan obtained at baseline. The primary tumors were mainly colorectal cancer (in 45%) or lung cancer (in 40%). iPA18F-FDG PET/CT was performed to identify any residual viable tumor cells. The treatment was considered a success (no viable tumor cells present) if no uptake of 18F-FDG was noted on the iPA18F-FDG PET/CT scan. Results: Twenty-six lesions were submitted to percutaneous ablation with either cryoablation (n = 7) or radiofrequency ablation (n = 19). The mean lesion diameter was 2.52 ± 1.49 cm. For the detection of viable tumor cells, iPA18F-FDG PET/CT had a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 66.7%, 95%, 88.5%, 80%, and 90.5%, respectively. There was a significant correlation between the iPA18F-FDG PET/CT findings and the results of the follow-up studies (kappa = 0.66; p < 0.01). Conclusion: iPA18F-FDG PET/CT studies appear to constitute a useful means of evaluating the outcomes of percutaneous ablation. By detecting residual viable tumor cells, this strategy might allow early re-intervention, thus reducing morbidity. Studies involving larger numbers of patients are needed in order to confirm our findings.

Download Full-text

Carbon 11–labeled methionine positron emission tomography for detection of residual viable tumor cells after adjuvant therapy in nongerminomatous malignant germ cell tumors in 2 cases including an autopsy case

Surgical Neurology ◽

10.1016/j.surneu.2007.07.013 ◽

2009 ◽

Vol 71 (1) ◽

pp. 83-88 ◽

Cited By ~ 2

Author(s):

Hideo Nakamura ◽

Keishi Makino ◽

Jun-ichi Kuratsu

Keyword(s):

Positron Emission Tomography ◽

Adjuvant Therapy ◽

Germ Cell ◽

Tumor Cells ◽

Germ Cell Tumors ◽

Emission Tomography ◽

Autopsy Case ◽

Positron Emission ◽

Malignant Germ Cell Tumors ◽

Residual Viable Tumor

Download Full-text

Liver Transplantation for Hepatocellular Carcinoma With No Viable Tumor Cells as a Result of Locoregional Therapy.

Transplantation Journal ◽

10.1097/00007890-201407151-02383 ◽

2014 ◽

Vol 98 ◽

pp. 700

Author(s):

S. Lee ◽

C. Kwon ◽

S. Shin ◽

K. Lee ◽

J. Rhu ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Transplantation ◽

Tumor Cells ◽

Locoregional Therapy ◽

Viable Tumor

Download Full-text

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer

JAMA Oncology ◽

10.1001/jamaoncol.2020.2295 ◽

2020 ◽

Vol 6 (9) ◽

pp. 1410 ◽

Cited By ~ 8

Author(s):

Milan Radovich ◽

Guanglong Jiang ◽

Bradley A. Hancock ◽

Christopher Chitambar ◽

Rita Nanda ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Disease Recurrence ◽

Circulating Tumor Dna ◽

Tumor Dna

Download Full-text

Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy

Clinical Breast Cancer ◽

10.1016/j.clbc.2020.02.006 ◽

2020 ◽

Vol 20 (4) ◽

pp. 332-343.e3

Author(s):

Mustafa Akkiprik ◽

Sinan Koca ◽

M. Ümit Uğurlu ◽

Rüçhan Ekren ◽

İrem Peker Eyüboğlu ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Advanced Breast Cancer ◽

Tumor Cells ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Response Assessment ◽

Microrna Profiling ◽

Plasma Microrna

Download Full-text

ATL

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000001352 ◽

2018 ◽

Vol 28 (8) ◽

pp. 1498-1506 ◽

Cited By ~ 4

Author(s):

Tatyana V. Gorodnova ◽

Khristina B. Kotiv ◽

Alexandr O. Ivantsov ◽

Olga N. Mikheyeva ◽

Galina I. Mikhailiuk ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Tumor Cells ◽

Mitomycin C ◽

Pathologic Complete Response ◽

Complete Response ◽

Tumor Burden ◽

Debulking Surgery ◽

Tumor Spread ◽

Primary Debulking Surgery

ObjectivesCisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).MethodsTwelve OC patients, who could not be treated by primary debulking surgery owing to extensive tumor spread, were given neoadjuvant cisplatin (100 mg/m2) and mitomycin C (10 mg/m2) every 4 weeks for 3 (n = 9), 2 (n = 2), or 4 (n = 1) cycles.ResultsThe decrease of tumor burden and complete surgical cytoreduction were achieved in all patients. Pathologic complete response, defined as the absence of tumor cells in surgically removed tissues, was observed in 2 (17%) of 12 cases. Retrospective analysis of 62 OC in BRCA1 mutation carriers subjected to conventional neoadjuvant chemotherapy schemes revealed 36 objective tumor responses (58%) and 37 instances (60%) of complete cytoreductive surgery; however, none of these patients demonstrated pathologic complete response.ConclusionsThe combination of cisplatin plus mitomycin C showed promising results in BRCA1-driven OC and therefore deserves further clinical evaluation.

Download Full-text